Exploring Sirtuins: New Frontiers in Managing Heart Failure with Preserved Ejection Fraction

被引：1
|
作者：
Lu, Ying [1 ]
Li, Yongnan [2 ]
Xie, Yixin [1 ]
Bu, Jiale [1 ]
Yuan, Ruowen [1 ]
Zhang, Xiaowei [1 ]
机构：
[1] Lanzhou Univ, Hosp 2, Dept Cardiol, Lanzhou 730031, Peoples R China
[2] Lanzhou Univ, Hosp 2, Dept Cardiac Surg, Lanzhou 730031, Peoples R China
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 14期
基金：
中国国家自然科学基金;
关键词：
SIRTs; heart failure; heart failure with preserved ejection fraction; left ventricular diastolic dysfunction; development; treatment; DIASTOLIC FUNCTION; CARDIAC FIBROSIS; SIRT1; ACTIVATOR; SEX-DIFFERENCES; MOUSE MODEL; GENDER; PROTECTS; SRT2104; HYPERTROPHY; RESISTANCE;
D O I：
10.3390/ijms25147740
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
With increasing research, the sirtuin (SIRT) protein family has become increasingly understood. Studies have demonstrated that SIRTs can aid in metabolism and affect various physiological processes, such as atherosclerosis, heart failure (HF), hypertension, type 2 diabetes, and other related disorders. Although the pathogenesis of HF with preserved ejection fraction (HFpEF) has not yet been clarified, SIRTs have a role in its development. Therefore, SIRTs may offer a fresh approach to the diagnosis, treatment, and prevention of HFpEF as a novel therapeutic intervention target.
引用
收藏
页数：22
相关论文
共 50 条
12345